Literature DB >> 10390245

Anti-Toxoplasma gondii activities and structure-activity relationships of novel fluoroquinolones related to trovafloxacin.

A A Khan1, F G Araujo, K E Brighty, T D Gootz, J S Remington.   

Abstract

Eleven novel fluoroquinolones closely related to trovafloxacin were evaluated for their in vitro activity against Toxoplasma gondii, and their structure-activity relationships were examined. The 50% inhibitory concentration (IC50) of trovafloxacin against T. gondii was 2.93 microM; the IC50 of the 11 analogs ranged from 0.53 to 14. 09 microM. Six analogs had IC50s lower than that of trovafloxacin. Examination of the structure-activity relationships of the compounds revealed that addition of a -CH3 at C-5 of the 1,8-naphthyridone ring, at C-2 of the azabicyclohexane ring, or on the -NH2 at the 6 position of the azabicyclohexane ring resulted in a four- to sixfold increase in activity. Moreover, replacement of 2,4-difluorophenyl by cyclopropyl at N-1 of the 1,8-naphthyridone ring increased activity twofold, and moving the -NH2 one atom further away from the azabicyclohexane ring decreased activity. There was no difference between the naphthyridone and quinolone analogs. These results indicate that structure-activity studies of compounds related to drugs active against T. gondii may be useful in producing compounds with more potent activities against the parasite.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10390245      PMCID: PMC89366     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  7 in total

1.  A plastid organelle as a drug target in apicomplexan parasites.

Authors:  M E Fichera; D S Roos
Journal:  Nature       Date:  1997-11-27       Impact factor: 49.962

Review 2.  DNA gyrase, topoisomerase IV, and the 4-quinolones.

Authors:  K Drlica; X Zhao
Journal:  Microbiol Mol Biol Rev       Date:  1997-09       Impact factor: 11.056

3.  Activity of trovafloxacin in combination with other drugs for treatment of acute murine toxoplasmosis.

Authors:  A A Khan; T Slifer; F G Araujo; R J Polzer; J S Remington
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

4.  Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones.

Authors:  X S Pan; L M Fisher
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

5.  Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii.

Authors:  F G Araujo; J Huskinson; J S Remington
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

6.  Trovafloxacin is active against Toxoplasma gondii.

Authors:  A A Khan; T Slifer; F G Araujo; J S Remington
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

7.  Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers.

Authors:  R Teng; S C Harris; D E Nix; J J Schentag; G Foulds; T E Liston
Journal:  J Antimicrob Chemother       Date:  1995-08       Impact factor: 5.790

  7 in total
  7 in total

1.  The effect of toxoplasmosis on the level of some sex hormones in males blood donors in Baghdad.

Authors:  Khawla Hori Zghair; Ban Nori Al-Qadhi; Suhad Hasan Mahmood
Journal:  J Parasit Dis       Date:  2013-11-21

2.  Anti-toxoplasma activities of 24 quinolones and fluoroquinolones in vitro: prediction of activity by molecular topology and virtual computational techniques.

Authors:  R Gozalbes; M Brun-Pascaud; R Garcia-Domenech; J Galvez; P M Girard; J P Doucet; F Derouin
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

3.  Catalytic Enantio- and Diastereoselective Cyclopropanation of 2-Azadienes for the Synthesis of Aminocyclopropanes Bearing Quaternary Carbon Stereogenic Centers.

Authors:  Xinxin Shao; Steven J Malcolmson
Journal:  Org Lett       Date:  2019-08-29       Impact factor: 6.005

4.  Activity of gatifloxacin alone or in combination with pyrimethamine or gamma interferon against Toxoplasma gondii.

Authors:  A A Khan; T R Slifer; F G Araujo; J S Remington
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

5.  In vitro activities of 25 quinolones and fluoroquinolones against liver and blood stage Plasmodium spp.

Authors:  Nassira Mahmoudi; Liliane Ciceron; Jean-François Franetich; Khemais Farhati; Olivier Silvie; Wijnand Eling; Robert Sauerwein; Martin Danis; Dominique Mazier; Francis Derouin
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

Review 6.  Drugs in development for toxoplasmosis: advances, challenges, and current status.

Authors:  P Holland Alday; Joseph Stone Doggett
Journal:  Drug Des Devel Ther       Date:  2017-01-25       Impact factor: 4.162

Review 7.  Antiviral, antifungal, and antiparasitic activities of fluoroquinolones optimized for treatment of bacterial infections: a puzzling paradox or a logical consequence of their mode of action?

Authors:  A Dalhoff
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-12-17       Impact factor: 3.267

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.